CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) saw a significant drop in short interest in April. As of April 15th, there was short interest totalling 23,100 shares, a drop of 53.8% from the March 31st total of 50,000 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 415,800 shares, the short-interest ratio is presently 0.1 days.
Hedge Funds Weigh In On CNS Pharmaceuticals
An institutional investor recently bought a new position in CNS Pharmaceuticals stock. Smith Anglin Financial LLC bought a new stake in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $64,000. Smith Anglin Financial LLC owned about 0.95% of CNS Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 14.02% of the company’s stock.
CNS Pharmaceuticals Stock Performance
CNSP traded up $0.01 during trading on Friday, reaching $0.22. The stock had a trading volume of 109,097 shares, compared to its average volume of 359,958. The stock has a market cap of $2.32 million, a PE ratio of -0.04 and a beta of 2.67. CNS Pharmaceuticals has a one year low of $0.19 and a one year high of $2.98. The business has a 50-day moving average of $0.31 and a 200-day moving average of $1.00.
CNS Pharmaceuticals Company Profile
CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
Featured Stories
- Five stocks we like better than CNS Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Investors Need to Know to Beat the Market
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
